Literature DB >> 23722541

Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.

Yu-Ching Teng1, Cheng-Feng Lee, Ying-Shiuan Li, Yi-Ren Chen, Pei-Wen Hsiao, Meng-Yu Chan, Feng-Mao Lin, Hsien-Da Huang, Yen-Ting Chen, Yung-Ming Jeng, Chih-Hung Hsu, Qin Yan, Ming-Daw Tsai, Li-Jung Juan.   

Abstract

The retinoblastoma binding protein RBP2 (KDM5A) is a histone demethylase that promotes gastric cancer cell growth and is enriched in drug-resistant lung cancer cells. In tumor-prone mice lacking the tumor suppressor gene RB or MEN1, genetic ablation of RBP2 can suppress tumor initiation, but the pathogenic breadth and mechanistic aspects of this effect relative to human tumors have not been defined. Here, we approached this question in the context of lung cancer. RBP2 was overexpressed in human lung cancer tissues where its depletion impaired cell proliferation, motility, migration, invasion, and metastasis. RBP2 oncogenicity relied on its demethylase and DNA-binding activities. RBP2 upregulated expression of cyclins D1 and E1 while suppressing the expression of cyclin-dependent kinase inhibitor p27 (CDKN1B), each contributing to RBP2-mediated cell proliferation. Expression microarray analyses revealed that RBP2 promoted expression of integrin-β1 (ITGB1), which is implicated in lung cancer metastasis. Mechanistic investigations established that RBP2 bound directly to the p27, cyclin D1, and ITGB1 promoters and that exogenous expression of cyclin D1, cyclin E1, or ITGB1 was sufficient to rescue proliferation or migration/invasion, respectively. Taken together, our results establish an oncogenic role for RBP2 in lung tumorigenesis and progression and uncover novel RBP2 targets mediating this role. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23722541     DOI: 10.1158/0008-5472.CAN-12-3165

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

Review 1.  Epigenetic regulation of epithelial-mesenchymal transition.

Authors:  Lidong Sun; Jia Fang
Journal:  Cell Mol Life Sci       Date:  2016-07-08       Impact factor: 9.261

Review 2.  JARID1 Histone Demethylases: Emerging Targets in Cancer.

Authors:  Kayla M Harmeyer; Nicole D Facompre; Meenhard Herlyn; Devraj Basu
Journal:  Trends Cancer       Date:  2017-09-12

3.  Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma.

Authors:  Hiroto Ohguchi; Paul M C Park; Tingjian Wang; Berkley E Gryder; Daisuke Ogiya; Keiji Kurata; Xiaofeng Zhang; Deyao Li; Chengkui Pei; Takeshi Masuda; Catrine Johansson; Virangika K Wimalasena; Yong Kim; Shinjiro Hino; Shingo Usuki; Yawara Kawano; Mehmet K Samur; Yu-Tzu Tai; Nikhil C Munshi; Masao Matsuoka; Sumio Ohtsuki; Mitsuyoshi Nakao; Takashi Minami; Shannon Lauberth; Javed Khan; Udo Oppermann; Adam D Durbin; Kenneth C Anderson; Teru Hideshima; Jun Qi
Journal:  Cancer Discov       Date:  2021-04-10       Impact factor: 39.397

4.  Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism.

Authors:  Idelisse Ortiz Torres; Kristopher M Kuchenbecker; Chimno I Nnadi; Robert J Fletterick; Mark J S Kelly; Danica Galonić Fujimori
Journal:  Nat Commun       Date:  2015-02-17       Impact factor: 14.919

5.  Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A.

Authors:  John R Horton; Xu Liu; Lizhen Wu; Kai Zhang; John Shanks; Xing Zhang; Ganesha Rai; Bryan T Mott; Daniel J Jansen; Stephen C Kales; Mark J Henderson; Katherine Pohida; Yuhong Fang; Xin Hu; Ajit Jadhav; David J Maloney; Matthew D Hall; Anton Simeonov; Haian Fu; Paula M Vertino; Qin Yan; Xiaodong Cheng
Journal:  J Med Chem       Date:  2018-03-23       Impact factor: 7.446

6.  Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.

Authors:  Yukihiro Itoh; Hideyuki Sawada; Miki Suzuki; Toshifumi Tojo; Ryuzo Sasaki; Makoto Hasegawa; Tamio Mizukami; Takayoshi Suzuki
Journal:  ACS Med Chem Lett       Date:  2015-04-23       Impact factor: 4.345

7.  Histone demethylase RBP2 is critical for breast cancer progression and metastasis.

Authors:  Jian Cao; Zongzhi Liu; William K C Cheung; Minghui Zhao; Sophia Y Chen; Siew Wee Chan; Carmen J Booth; Don X Nguyen; Qin Yan
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

8.  Double duty: ZMYND8 in the DNA damage response and cancer.

Authors:  Fade Gong; Kyle M Miller
Journal:  Cell Cycle       Date:  2018-03-19       Impact factor: 4.534

9.  Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase.

Authors:  Samuel K McBrayer; Benjamin A Olenchock; Gabriel J DiNatale; Diana D Shi; Januka Khanal; Rebecca B Jennings; Jesse S Novak; Matthew G Oser; Alissa K Robbins; Rebecca Modiste; Dennis Bonal; Javid Moslehi; Roderick T Bronson; Donna Neuberg; Quang-De Nguyen; Sabina Signoretti; Julie-Aurore Losman; William G Kaelin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-02       Impact factor: 11.205

10.  A UHPLC-MS/MS method for the quantification of JIB-04 in rat plasma: Development, validation and application to pharmacokinetics study.

Authors:  Yang Wang; Jing Ma; Elisabeth D Martinez; Dong Liang; Huan Xie
Journal:  J Pharm Biomed Anal       Date:  2020-08-25       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.